How to Prevent Passing CMT1A to Children | Inciteful Med

Yes, it is absolutely possible to have a biological child who does not have Charcot-Marie-Tooth disease type 1A (CMT1A). Family planning can be a significant source of stress and guilt for individuals with genetic conditions. However, medical technology offers a clear path forward: a process called In Vitro Fertilization (IVF) combined with Preimplantation Genetic Testing for Monogenic disorders (PGT-M). This combination allows doctors to test embryos for the exact CMT1A genetic mutation before a pregnancy begins, ensuring only embryos without the condition are transferred to the uterus ^[1][2]. While some families choose to conceive unassisted and use prenatal testing (such as CVS or amniocentesis) during the pregnancy, IVF with PGT-M is often preferred by those who want to avoid the difficult decisions associated with an affected pregnancy.

Understanding the Risk: Autosomal Dominant Inheritance

CMT1A is caused by an extra copy (a duplication) of the PMP22 gene located on chromosome 17 ^[3].

The condition follows an autosomal dominant inheritance pattern. This means that an individual only needs one copy of the duplicated gene to have the disease. If one biological parent has CMT1A, there is a 50% chance with each natural pregnancy that the child will inherit the extra gene and develop the condition ^[4].

The severity of CMT1A is also highly variable. Even within the same family, one person might have very mild symptoms while another might experience significant muscle weakness, sensory loss, or require mobility aids ^[5][6]. Because it is impossible to predict how severe the disease will be in a child, many prospective parents choose to explore genetic screening.

How the IVF and PGT-M Process Works

Using IVF and PGT-M to prevent passing on CMT1A involves several specialized steps:

1. Genetic Counseling and Test Design

Before starting the physical IVF process, you will work with a genetic counselor ^[7]. Because CMT1A is caused by a gene duplication (rather than a simple spelling mistake in the DNA), scientists must build a customized test—often called a “probe”—specific to your family’s unique genetics ^[8]. To build this test using advanced sequencing techniques, the lab will likely need blood or saliva samples from the patient with CMT1A, their partner, and sometimes parents or siblings ^[9][10].

Timeline note: Developing this custom probe typically takes several weeks to months (often 8 to 12 weeks) before the actual IVF cycle can begin.

2. Egg Retrieval and Fertilization (IVF)

The partner providing the eggs will take hormone medications to stimulate the ovaries to produce multiple eggs. These eggs are then retrieved during a minor surgical procedure.

Important safety note for CMT1A patients: If the partner undergoing the egg retrieval is the one with CMT1A, it is crucial to discuss anesthesia safety with the care team prior to the procedure. CMT1A can sometimes affect the muscles involved in breathing, leading to diaphragmatic weakness ^[11][5].

Once retrieved, the eggs are fertilized with sperm in a laboratory to create embryos.

3. Embryo Biopsy and Testing

After the embryos grow in the lab for a few days, an embryologist safely removes a few cells from each one ^[8]. The laboratory tests these cells specifically for the PMP22 duplication.

Doctors also frequently recommend performing PGT-A (aneuploidy screening) at the same time ^[12]. PGT-A is an optional but highly utilized test that checks to make sure the embryo has the correct overall number of chromosomes, which significantly reduces the risk of miscarriage ^[13].

4. Embryo Transfer

Once the testing is complete, the medical team will identify the healthy embryos that do not carry the CMT1A duplication. One of these embryos is then transferred to the uterus to attempt to establish a pregnancy ^[4].

Success Rates and Considerations

PGT-M is a highly accurate and reliable method for preventing the transmission of single-gene disorders like CMT1A ^[14][15]. However, there are important realities to consider before starting:

• Age and Egg Supply: The overall success of taking a baby home depends heavily on the maternal age and the number of eggs retrieved ^[16][17]. Because some embryos will test positive for CMT1A and others might have different chromosomal issues, starting with a higher number of eggs is highly advantageous.
• Financial and Emotional Toll: The process is often physically, emotionally, and financially taxing. Insurance coverage for IVF and custom PGT-M probes varies widely, so it is highly recommended to consult with a clinic’s financial coordinator early in the process.
• Pregnancy Monitoring: While PGT-M successfully protects against CMT1A, pregnancies conceived via IVF carry a slightly increased risk of obstetric complications (such as high blood pressure during pregnancy) compared to unassisted pregnancies ^[18]. Close monitoring by an obstetrician is essential.